Prostate Cancer Therapeutics Market: Information by Type of Therapy (Hormonal Therapy), Distribution Channel (Hospital Pharmacies, Online Sales), and Region — Forecast till 2029

The prostate is a compound tubuloalveolar exocrine gland of the male reproductive system. Most prostate cancers develop slowly; there are, however, cases of aggressive prostate cancers. Cancer cells can metastasize (spread) to other parts of the body from the prostate, particularly the bones and lymph nodes. Prostate cancer is the second leading cause of new cancer cases in males worldwide and the sixth leading cause of death in males due to cancer.

The demand for therapeutics is now higher than before on account of the rising prevalence of prostate cancer. Statistically, the American Society of Clinical Oncology has predicted that an estimated 191,930 men will be diagnosed with prostate cancer in the U.S. in 2020.

The prostate cancer therapeutics market was valued at USD 10,368 million in 2019 and is expected to grow with a CAGR of 8% during the forecast period.

Request For Sample Report : https://straitsresearch.com/report/prostate-cancer-therapeutics-market/request-sample

Prostate Cancer Therapeutics Market: Segmentation

Hospitals Active Participation to Search a Better Cure for Prostate Cancer Drives the Market Growth

Hospitals remain the predominant medium of care, despite the increasing number of outpatient surgical centers and clinics focused on providing therapies for prostate cancer treatment. This leads to strong sales by hospital pharmacies of prostate cancer therapeutics, which are expected to account for a substantial amount of market share. Also, the segment is expected to witness momentum due to an increase in admissions of geriatric patients in hospitals and laboratories for the diagnosis of old age-related disease. In addition, hospitals internationally are introducing innovative and efficient techniques, such as drug repositioning, to treat prostate cancer efficiently without dangerous side effects.

Hormonal Therapy Dominates the Market during the Forecast Period

The hormone therapy segment dominates the prostate cancer therapeutics market during the forecast period. Hormonal therapy aims to reduce levels of male hormones, androgens, in the body; thus, stopping them from fueling prostate cancer cells. Additionally, the therapy is low cost and gives a better market reach.

However, the rapid development and adoption of immunotherapy drugs are expected to result in the fast growth of this drug class. In cases where the patient's prostate cancer is resistant to testosterone level reduction via hormone therapy, treatment options become very limited. Immunotherapy can be used in such conditions for therapeutic actions. Presently, only two FDA approved options for immunotherapy are available in the prostate cancer market, Sipuleucel-T (Cancer Vaccine) and Pembrolizumab (Immunomodulators). However, for patients with advanced prostate cancer, multiple immunotherapy options are currently in clinical trials.
Prostate Cancer Therapeutics Market: Segmentation

Hospitals Active Participation to Search a Better Cure for Prostate Cancer Drives the Market Growth

Hospitals remain the predominant medium of care, despite the increasing number of outpatient surgical centers and clinics focused on providing therapies for prostate cancer treatment. This leads to strong sales by hospital pharmacies of prostate cancer therapeutics, which are expected to account for a substantial amount of market share. Also, the segment is expected to witness momentum due to an increase in admissions of geriatric patients in hospitals and laboratories for the diagnosis of old age-related disease. In addition, hospitals internationally are introducing innovative and efficient techniques, such as drug repositioning, to treat prostate cancer efficiently without dangerous side effects.

Hormonal Therapy Dominates the Market during the Forecast Period

The hormone therapy segment dominates the prostate cancer therapeutics market during the forecast period. Hormonal therapy aims to reduce levels of male hormones, androgens, in the body; thus, stopping them from fueling prostate cancer cells. Additionally, the therapy is low cost and gives a better market reach.

However, the rapid development and adoption of immunotherapy drugs are expected to result in the fast growth of this drug class. In cases where the patient's prostate cancer is resistant to testosterone level reduction via hormone therapy, treatment options become very limited. Immunotherapy can be used in such conditions for therapeutic actions. Presently, only two FDA approved options for immunotherapy are available in the prostate cancer market, Sipuleucel-T (Cancer Vaccine) and Pembrolizumab (Immunomodulators). However, for patients with advanced prostate cancer, multiple immunotherapy options are currently in clinical trials.

Buy Now : https://straitsresearch.com/buy-now/prostate-cancer-therapeutics-market/global/

Key Players

Amgen, Inc. (The U.S.)
Johnson & Johnson (The U.S.)
Pfizer, Inc. (The U.S.)
AstraZeneca (The U.S.)
AbbVie, Inc. (The U.S.)
Bayer AG (Germany)
Ipsen Group (France)
Sanofi (France)
Endo Pharmaceuticals, Inc. (Ireland)
Dendreon Corporation (The U.S.)
Recent Developments

In May 2020, ZydusCadila introduced generic Enzalutamide capsules used for the treatment of prostate cancer, which cost almost 70% less than the related drugs currently available in India
In 2020, a research group from the Cancer Research Institute and the University of South Australia has developed a novel formulation of the prostate cancer drug abiraterone acetate, which is currently marketed as Zytiga. The group believes that this would significantly boost the quality of life of people who have prostate cancer, as the current formulation increases the efficacy of the medication by 40%.
Prostate Cancer Therapeutics Market: Segmentation

By Type of Therapy

Hormonal Therapy
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
LHRH Antagonist
Anti-Androgen
Chemotherapy
Systemic Chemotherapy
Regional Chemotherapy
Cryotherapy
Radiation Therapy
Targeted Therapy
Immunotherapy
Biologic Therapy
By Distribution Channel

Hospital Pharmacies
Online Sales
Retail Pharmacies
By Region

North America

The U.S.
Canada
Mexico
Europe

Germany
The U.K.
France
Italy
Spain
Russia
The Rest of Europe
Asia-Pacific

China
Japan
India
Korea
Australia
Southeast Asia
The Rest of Asia-Pacific
Central and South America and the Caribbean

Brazil
Argentina
Chile
The Rest of Central and South America and the Caribbean
The Middle East and Africa

South Africa
Egypt
The UAE
Saudi Arabia
The Rest of MEA

Contact Us:
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY, USA, 10022
Tel: +1 6464807505, +44 203 318 2846
Website: https://straitsresearch.com/

About Us :
StraitsResearch.com is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.

This release was published on openPR.